JohnMSharrettsMD
Endocrinology • Philadelphia, PADiabetes, Lipid Metabolism
Assistant Professor, Medicine, Perelman School of Medicine
Dr. Sharretts is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Boulevard
West Pavilion, 4th Floor
Philadelphia, PA 19104Phone+1 215-662-2300
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2008 - 2011
MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 1995 - 1999
Greater Baltimore Medical CenterInternship, Transitional Year, 1994 - 1995
Virginia Commonwealth University School of MedicineClass of 1994
Certifications & Licensure
DC State Medical License 1997 - 2024
MD State Medical License 1999 - 2015
PA State Medical License 2011 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- 71 citationsCancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 TrialJohn Sharretts, Ovidiu Galescu, Shanti Gomatam, Eugenio Andraca-Carrera, Christian Hampp
The New England Journal of Medicine. 2020-09-09 - 79 citationsClinical and molecular genetics of parathyroid neoplasmsJohn Sharretts, William F. Simonds
Best Practice & Research. Clinical Endocrinology & Metabolism. 2010-06-01 - 21 citationsConversion from Intravenous Insulin to Subcutaneous Insulin After Cardiovascular Surgery: Transition to Target StudyMansur E. Shomali, Daniel Herr, Peter C. Hill, Marieta Pehlivanova, John M. Sharretts
Diabetes Technology & Therapeutics. 2011-02-01
Press Mentions
Novo’s Semaglutide Scores in Liver Fibrosis and MASH TrialNovember 4th, 2024- Wegovy vs. Ozempic: The Truth About These New Weight-Loss DrugsApril 6th, 2023
- FDA Approves First Drug to Delay Onset of Type 1 DiabetesNovember 28th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
